FDA digital health leader promises generative AI regulatory guidance is coming

Rick Abramson, director of the agency's Digital Health Center of Excellence, said the agency will eventually release documents spelling out its policies. The article's headline describes the guidance as coming, but no date is given for its release.

Abramson said the agency is developing the plan, and that documents will eventually spell out agency policies. No timeline was provided for the documents, and no details were offered about their likely content. The article does not indicate whether the eventual documents would be binding regulation or non-binding guidance. It does not describe any other FDA officials or outside participants.

The report frames the announcement as a commitment to future action rather than a description of specific rules. Device makers are left with limited information about how the FDA intends to approach generative AI in their products. The article does not mention any other agencies, companies, or policy proposals. It presents the development as an early-stage internal effort. The practical implications of the promised guidance remain unspecified.